Advertisement

Picture EBD Group BIO-Europe 2021 Digital BEU2021 650x80
Product › Details

Vitrakvi®

Products Next higher product group larotrectinib (LOXO-101)
Period Status 2018-11-26 registration start
Organisation Organisation Loxo Oncology Inc.
  Group Eli Lilly (Group)
Document Source Bayer Corporation. (11/26/18). "Press Release: FDA Approves Vitrakvi (larotrectinib), the First Ever TRK Inhibitor, for Patients with Advanced Solid Tumors Harboring an NTRK Gene Fusion". Whippany, NJ & Stamford, CT.
     

   
Record changed: 2019-06-04

Advertisement

Picture EBD Group Connector Personal Networking in Life Sciences 650x80

More documents for larotrectinib (LOXO-101)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture EBD Group Global Partnering Four Events One Price 650x80




» top